Prescription switch studies: Objectives, methods and limits;Étude des reports de prescription: Objectifs, méthodes et limites

Therapie

Volumn 62, Issue 1, 2007, Pages 31-38

  Pradel, Vincent ^a   Micallef, Joëlle ^a   Blin, Olivier ^a,b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^b TIMONE HOSPITAL   (France)

Author keywords

Drug utilisation studies; Methods; Pharmacoeconomics; Pharmacoepidemiology; Prescription switch

Indexed keywords

ARTICLE; DRUG MARKETING; DRUG SUBSTITUTION; DRUG UTILIZATION; PATIENT DECISION MAKING; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PRIORITY JOURNAL; DRUG THERAPY; HUMAN; REVIEW;

DRUG THERAPY; DRUG UTILIZATION; HUMANS; PRESCRIPTIONS, DRUG;

EID: 34249690256     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie:2007011     Document Type: Article

References (34)

1. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003; 64(6): 663-667
2. Grosset K, Needleman F, Macphee G, et al. Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table. Mov Disord 2004; 19(11): 1370-1374
3. Dai C, Stafford RS, Alexander GC. National Trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation. Arch Intern Med 2005; 165: 171-177
4. CNAMTS (Caisse Nationale d'Assurance Maladie des Travailleurs Salariés). GENERICAM Les chiffres-clés des médicaments génériques remboursés par le Régime Général en 2000 et en 2001. No55, juin 2003. Paris, 2003. http://www.ameli.fr/pdf/1007.pdf
5. Reynolds T. Switching from prescription to over the counter. Ann Intern Med 2002 Jan 15; 136(2): 177-180
6. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy. Annual trends and response to recent evidence. JAMA 2004; 291: 47-53
7. Stafford RS, Furberg CD, Finkelstein SN, et al. Impact of clinical trial results on national trends in α-blocker prescribing, 1996-2002. JAMA 2004; 291: 54-62
8. Roberts I, Bunn F. Egg on their faces. The story of human albumin solution. Eval Health Prof 2002; 25(1): 130-138
9. Orlowski JP, Wateska L. The effects of pharmaceutical firm enticements on physician prescribing patterns. There's no such thing as a free lunch. Chest 1992; 102(1): 270-273
10. Caudill TS, Johnson MS, Rich EC, et al. Physicians, pharmaceutical sales representatives, and the cost of prescribing Arch Fam Med 1996; 5(4): 201-206
11. Donohue JM, Berndt ER, Rosenthal M, et al. Effects of pharmaceutical promotion on adherence to the treatment guidelines for depression. Med Care 2004; 42(12): 1176-1185
12. Fretheim A, Aaserud M, Oxman AD. The potential savings of using thiazides as the first choice antihypertensive drug: cost-minimisation analysis. BMC Health Serv Res 2003; 3(1): 18
13. URCAM Rhône-Alpes. Médicaments 2003 - La pharmacie en Rhône-Alpes - Edition 2003 URCAM Rhône-Alpes. http://www.rhone- alpes.assurance-maladie.fr/fileadmin/RHONE-ALPES/publications/ Pharmacie_en_RA_Rapport_2003.pdf
14. Observatoire National des Prescriptions et Consommations des Médicaments. Etude de la prescription et de la consommation des veinotoniques en ambulatoire. Agence du Médicament, Paris, 1999. http://afssaps.sante.fr/pdf/5/5017.pdf
15. Victorri-Vigneau C, Basset G, Bourin M, et al. Impacts de la nouvelle réglementation du flunitrazépam sur la consommation d'hypnotiques. Therapie 2003; 58(5): 425-430
16. Bartlett G, Abrahamowicz M, Tamblyn R, et al. Longitudinal patterns of new benzodiazepine use in the elderly. Pharmacoepidemiol Drug Saf 2004; 13(10): 669-682
17. Fourrier A, Letenneur L, Dartigues JF, et al. Benzodiazepine use in an elderly community-dwelling population. Characteristics of users and factors associated with subsequent use. Eur J Clin Pharmacol 2001; 57(5): 419-425
18. Walker AM, Chan KW, Yood RA. Patterns of interchange in the dispensing of non-steroidal anti-inflammatory drugs. J Clin Epidemiol 1992; 45(2): 187-195
19. Chan KW, Walker AM, Yood RA. An equilibrium model of drug utilization. J Clin Epidemiol 1993; 46(1): 113-121
20. Langman M, Kahler KH, Kong SX, et al. Drug switching patterns among patients taking non-steroidal anti-inflammatory drugs: a retrospective cohort study of a general practitioners database in the United Kingdom. Pharmacoepidemiol Drug Saf 2001; 10(6): 517-524
21. Hugenholtz GW, Heerdink ER, Nolen WA, et al. Less medication switching after initial start with atypical antipsychotics. Eur Neuropsychopharmacol 2004; 14(1): 1-5
22. Zhao SZ, Wentworth C, Burke TA, et al. Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs. Pharmacoepidemiol Drug Saf 2004; 13(5): 277-287
23. Bennett K, Teeling M, Feely J. "Selective" switching from non-selective to selective non-steroidal anti-inflammatory drugs. Eur J Clin Pharmacol 2003; 59(8-9): 645-649
24. Spoelstra JA, Stolk RP, Heerdink ER, et al. Refill compliance in type 2 diabetes mellitus: a predictor of switching to insulin therapy? Pharmacoepidemiol Drug Saf 2003; 12(2): 121-127
25. Crane J, Pearce N, Flatt A, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study. Lancet 1989; 1(8644): 917-922
26. Petri H, Urquhart J. Channeling bias in the interpretation of drug effects. Stat Med 1991; 10(4): 577-581
27. Blais L, Ernst P, Suissa S. Confounding by indication and channeling over time: the risks of beta2-agonists. Am J Epidemiol 1996; 144(12): 1161-1169
28. Suissa S. Novel approaches to pharmacoepidemiology study design and statsistical analysis. In: Strom BL Editor. Pharmacoepidemiology. 3rd edition. Chichester: John Wiley and Sons, 2000: 785-805
29. Strom BL Editor. Pharmacoepidemiology. 3rd edition. Chichester: John Wiley and Sons, 2000: 247-386
30. Blais L, Couture J, Rahme E, et al. Impact of a cost sharing drug insurance plan on drug utilization among individuals receiving social assistance. Health Policy 2003; 64(2): 163-172
31. Afssaps (Agence Française de Sécurité Sanitaire des Produits de Santé) 2005. Mise au point sur le traitement hormonal substitutif de la ménopause (THS) mise à jour : 2 mai 2005. http://agmed.sante.gouv.fr/htm/10/ths/indths.htm
32. Desgagné A, LeLorier J. Incontinence drug utilization patterns in Québec, Canada. Value in Health 1999; 2(6), 452-458
33. Leufkens HG. Pharmacoepidemiological modelling: markov models of antibiotic use in patients with diabetes. Neth J Med 2002; 60(7 Suppl):78-80; discussion 80-82
34. Sernyak MJ, Leslie D, Rosenheck R. Use of system-wide outcomes monitoring data to compare the effectiveness of atypical neuroleptic medications. Am J Psychiatry 2003; 160(2): 310-315